Show simple item record

dc.contributor.authorFinn, Stephenen
dc.contributor.authorFlavin, Richarden
dc.date.accessioned2016-01-07T15:44:06Z
dc.date.available2016-01-07T15:44:06Z
dc.date.issued2014en
dc.date.submitted2014en
dc.identifier.citationFlavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA, SPINK1 protein expression and prostate cancer progression., Clinical cancer research : an official journal of the American Association for Cancer Research, 20, 18, 2014, 4904-11en
dc.identifier.issn1078-0432en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/75504
dc.descriptionPUBLISHEDen
dc.description.abstractPURPOSE: SPINK1 overexpression has been described in prostate cancer and is linked with poor prognosis in many cancers. The objective of this study was to characterize the association between SPINK1 overexpression and prostate cancer-specific survival. EXPERIMENTAL DESIGN: The study included 879 participants in the U.S. Physicians' Health Study and Health Professionals Follow-Up Study, diagnosed with prostate cancer (1983-2004) and treated by radical prostatectomy. Protein tumor expression of SPINK1 was evaluated by immunohistochemistry on tumor tissue microarrays. RESULTS: Seventy-four of 879 (8%) prostate cancer tumors were SPINK1 positive. Immunohistochemical data were available for PTEN, p-Akt, pS6, stathmin, androgen receptor (AR), and ERG (as a measure of the TMPRSS2:ERG translocation). Compared with SPINK1-negative tumors, SPINK1-positive tumors showed higher PTEN and stathmin expression, and lower expression of AR (P < 0.01). SPINK1 overexpression was seen in 47 of 427 (11%) ERG-negative samples and in 19 of 427 (4%) ERG-positive cases (P = 0.0003). We found no significant associations between SPINK1 status and Gleason grade or tumor stage. There was no association between SPINK1 expression and biochemical recurrence (P = 0.56). Moreover, there was no association between SPINK1 expression and prostate cancer mortality (there were 75 lethal cases of prostate cancer during a mean of 13.5 years follow-up; HR = 0.71; 95% confidence interval, 0.29-1.76). CONCLUSIONS: Our results suggest that SPINK1 protein expression may not be a predictor of recurrence or lethal prostate cancer amongst men treated by radical prostatectomy. SPINK1 and ERG protein expression do not seem to be entirely mutually exclusive, as some previous studies have suggested.en
dc.format.extent4904-11en
dc.relation.ispartofseriesClinical cancer research : an official journal of the American Association for Cancer Researchen
dc.relation.ispartofseries20en
dc.relation.ispartofseries18en
dc.rightsYen
dc.subjectProstate canceren
dc.titleSPINK1 protein expression and prostate cancer progression.en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/finnsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/flavinren
dc.identifier.rssinternalid109665en
dc.identifier.doihttp://dx.doi.org/10.1158/1078-0432.CCR-13-1341en
dc.rights.ecaccessrightsopenAccess
dc.identifier.orcid_id0000-0002-8628-5814en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record